{"url_path":"/sec/prld/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 [Financial Statements](#item_1_financial_statements)","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-218173-index.html","accession_number":"0001193125-26-218173","cik":"0001678660","ticker":"PRLD","issuer_name":"Prelude Therapeutics Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-218173-index.html","primary_entity_key":"0001678660","primary_entity_name":"Prelude Therapeutics Inc"},"word_count":38,"has_tables":true,"body_markdown":"Item 1.\n\n[Financial Statements](#item_1_financial_statements)\n\n1\n\n[Balance Sheets (Unaudited)](#balance_sheets)\n\n1\n\n[Statements of Operations and Comprehensive Loss (Unaudited)](#statements_operations)\n\n2\n\n[Statements of Changes in Stockholders’ Equity (Unaudited)](#statements_changes_in_convertible_prefer)\n\n3\n\n[Statements of Cash Flows (Unaudited)](#statements_cash_flows)\n\n4\n\n[Notes to Unaudited Interim Financial Statements](#notes_to_unaudited_interim_financial_sta)\n\n5"}